MediGene Signs Veregen Commercialization Agreement with SynCore Bio in Taiwan
24-May-2011 -
MediGene AG has signed an exclusive license and supply agreement with SynCore Bio, a subsidiary of the Sinphar Group, for the commercialization and marketing of Veregen® ointment in Taiwan for the treatment of genital warts. MediGene will supply Sinphar with API, Sinphar will produce the drug in ...
genital warts
MediGene
Taiwan
+1